We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
SCT Changes its Name to Trillium Therapeutics Inc.
News

SCT Changes its Name to Trillium Therapeutics Inc.

SCT Changes its Name to Trillium Therapeutics Inc.
News

SCT Changes its Name to Trillium Therapeutics Inc.

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "SCT Changes its Name to Trillium Therapeutics Inc."

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Stem Cell Therapeutics Corp. has announced that it has filed articles of amalgamation to merge with its wholly-owned subsidiary Trillium Therapeutics Inc. (“TTI”). The combined company has adopted the Trillium name.

“The use of "Stem Cell" in our company name did not properly reflect our business, which is strongly focused on the immuno-oncology area, such as our checkpoint inhibitor program targeting the CD47/SIRPa immunoregulatory axis”, commented Dr. Niclas Stiernholm, Chief Executive Officer.

Dr. Stiernholm continued, “Trillium enjoyed a solid reputation in the biopharmaceutical industry for its high quality immunotherapy research, exemplified by a decade of strong industry and academic partnerships. We will clearly benefit from this brand recognition with our return to the Trillium name.”

Conditional approval for the name change was received from the TSX. The Company will soon begin trading under the symbol “TR”.

Advertisement